For the Inventor, By the Inventor

Enter assignee name

Convergence Pharmaceuticals Limited

USPTO Granted Patents = 24

CIPO Patents = 1

EPO Patents = 17

Forward Citations = 65

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Gerard M P Giblin (7 out of 7 patents)

Steven J Stanway (7 out of 7 patents)

David Witty (6 out of 10 patents)

4. David MacPherson (5 out of 5 patents)

5. Paul John Beswick (5 out of 28 patents)

6. Robert James Gleave (5 out of 8 patents)

7. Jag Paul Heer (5 out of 10 patents)

8. Sadie Vile (5 out of 7 patents)

9. Giuseppe Alvaro (4 out of 58 patents)

10. David Norton (4 out of 15 patents)

11. Andrew Peter Cridland (4 out of 20 patents)

12. Markus Bergauer (4 out of 8 patents)

13. Roberto Profeta (4 out of 6 patents)

14. Simon Edward Ward (4 out of 15 patents)

15. David T MacPherson (3 out of 4 patents)

24 patents: Sort by Forward Citations

1. 10493059 - Paroxysmal extreme pain disorder treatment (2019-12-03),

2. 10485801 - Pyrimidinyl-diazospiro compounds (2019-11-26),

3. 10421716 - Process for preparing alpha-carboxamide pyrrolidine derivatives (2019-09-24),

4. 10231950 - Erythromelalgia treatment (2019-03-19),

5. 10010551 - Pyrimidinyl-diazospiro compounds (2018-07-03),

6. 9750719 - Tetrazole compounds as calcium channel blockers (2017-09-05),

7. 9737536 - Pyrimidinyl-diazospiro compounds (2017-08-22),

8. 9376445 - Pyrimidinyl-diazospiro compounds (2016-06-28),

9. 9376436 - 2-(pyridin-2yl)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulators (2016-06-28),

10. 9309254 - Pyrimidinyl-diazospiro compounds (2016-04-12),

11. 9303032 - 2-(pyridin-2YL)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulator (2016-04-05),

12. 9115132 - Tetrazole compounds as calcium channel blockers (2015-08-25),

13. 9045485 - ASK 1 inhibiting pyrrolopyrimidine derivatives (2015-06-02),

14. 8933132 - Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers (2015-01-13),

15. 8759542 - Process for preparing alpha-carboxamide derivatives (2014-06-24),

Convergence Pharmaceuticals Limited is a leading biopharmaceutical company focused on discovering and developing novel medicines for the treatment of chronic pain. With a team of dedicated researchers and state-of-the-art facilities, Convergence Pharma is committed to making a positive impact on the lives of patients suffering from debilitating pain conditions. By combining innovative science, cutting-edge technologies, and strategic partnerships, the company aims to bring breakthrough therapies to market that provide significant relief and improve the quality of life for those in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

24 Patents

#51 in

#735 in United Kingdom

#25,864 in the World

Convergence Pharmaceuticals Limited

Forward Citations = 65

41 inventors:

Gerard M P Giblin (7 out of 7 patents)

Steven J Stanway (7 out of 7 patents)

David Witty (6 out of 10 patents)

4. David MacPherson (5 out of 5 patents)

5. Paul John Beswick (5 out of 28 patents)

Please report any incorrect information to support@idiyas.com

Loading…